The company reported Health Canada authorized the use of its Spikevax KP.2 shot for those aged six months and older. Last ...

Jim Cramer’s 10 Best Stock Picks for Investors Right Now. In this article, we are going to take a look at where Moderna, Inc.

But Moderna's news hasn't been as bright recently. Last month, the company revised coronavirus vaccine revenue downward due to lower sales. And in its update this week, the biotech made ...

days after new mRNA coronavirus vaccines manufactured by Pfizer-BioNTech and Moderna started hitting pharmacies. Health officials encourage annual vaccination against the coronavirus, similar to ...

Moderna, Inc.'s combination flu and COVID-19 vaccine, mRNA-1083, showed strong Phase 3 results in adults over 50. Pfizer/BioNTech's combination vaccine faced setbacks, giving Moderna a potential ...

The Food and Drug Administration approved Novavax’s new COVID-19 vaccine Friday, a week after giving Pfizer and Moderna the OK on their shots, though all drugmakers say their shots will be ...

Moderna shares have dropped by over -41.67% since I last covered them over the summer. See why I continue to rate MRNA stock ...

Also Read: Struggling COVID-19 Vaccines From AstraZeneca, BioNTech/Pfizer, Moderna Cut Incidence Of Arterial Thromboses That Cause Heart Attacks, Strokes, British Study Shows. In early June ...

Shares of Moderna tumbled early Thursday after the vaccine developer said it was cutting research and development spending and pushed back its time frame for breaking even Shares of Moderna ...

Expanding its portfolio into oncology and rare diseases, positions Moderna to deliver ten product approvals within the next three years. The analyst notes the COVID-19 vaccine maker pushed its ...

An updated COVID-19 vaccine is coming to Canada just in time for fall. On Tuesday, Health Canada announced it had approved Moderna’s latest COVID vaccine that’s been reformulated to target prevalent ...

Shares of Moderna tumbled early Thursday after the vaccine developer said it was cutting research and development spending and pushed back its time frame for breaking even. The company also ...